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Abstract
Background and aims: Carbapenems are the final-line treatments for multidrug-resistant, gram-negative infections. The patterns of resistance 
to carbapenems among hospital bacterial pathogens vary widely across different hospitals in a country. Considering that Escherichia coli is 
one of the most important causes of nosocomial infections, it is essential to study its drug resistance.
Methods: In this descriptive-analytical study, a total of 80 samples of E. coli isolated from inpatients with urinary tract infections (UTIs) 
were collected in different wards (i.e., women, urology, infectious, and ICU) of Shahrekord hospitals. After the diagnosis and confirmation 
of bacteria by standard bacteriological methods, their sensitivity to imipenem and meropenem was investigated by the antibiogram (disk-
diffusion) method. Then, the minimum inhibitory concentration (MIC) was determined by the E-test strip according to the Clinical and 
Laboratory Standards Institute (CLSI) standard.
Results: In this study, resistance to meropenem and imipenem by antibiogram (disc diffusion) was observed in 21 (25.26%) and 20 (25%) 
of the isolates, respectively. Twenty isolates had MIC ≥4 μg/mL for meropenem, 13 isolates demonstrated MIC≥4 μg/mL for imipenem, and 
14 isolates had 1≤MIC<4 μg/mL and were semi-sensitive.
Conclusion: In general, E. coli had significant resistance to carbapenems. Therefore, rapid and accurate identification of these strains can 
be a major step to the treatment and control of these strains and prevention of the spread of the resistance.
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Introduction 
Microorganisms causing nosocomial infections lead to 
severe problems for patients and the health system due 
to antibiotic resistance (1). In some countries, the rate of 
nosocomial infections is high due to the lack of monitoring, 
the lack of infection prevention, the inappropriate use of 
antibiotics, and excessive overcrowding in the hospitals 
(2). According to Yang et al, the Enterobacteriaceae family, 
particularly Escherichia coli, is responsible for various types 
of infections, especially urinary tract infections (UTIs). 
These infections account for 30%-40% of nosocomial 
infections and are the most common cause of gram-negative 
septicemia in inpatients (4,5). The most common etiologic 
factor for UTI is E. coli, which accounts for most of these 
cases (6,7). Carbapenems include ertapenem, imipenem, 
doripenem, and meropenem (8), which are nowadays 
regarded as selective drugs that are used to treat serious 
infections in multidrug-resistant Enterobacteriaceae 
and produce extended-spectrum β-lactamases (9,10). In 
fact, they are the final-line antibiotics for the treatment 
of multidrug resistance (11). In addition, carbapenems 
are considered as selective therapeutic agents for gram-
negative, penicillin- and cephalosporin-resistant bacterial 
infections due to their extended-spectrum and the 
lack of hydrolysis by β-lactamases enzymes (8). The 
excessive increase in antibiotic resistance among gram-
negative bacteria has challenged drug therapies (12,13). 
In this study, the frequency of E. coli strains resistant 
to meropenem and imipenem was investigated by the 
disk diffusion method, followed by determining their 
minimum inhibitory concentrations (MICs) by using the 
E-test strip. Clinicians can select appropriate antibiotics 
to rapidly eradicate the infections caused by carbapenems 
by obtaining information on the prevalence and rate of 
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resistance to these bacteria in E. coli isolates from UTI 
samples in different regions of Iran and across the world. 
It also avoids a waste of time, the futile consumption of 
drugs, or even an increase in resistance to the mentioned 
bacteria.
Materials and Methods
In this study, 80 E. coli isolates were collected from UTI 
inpatients in different wards of the hospitals (e.g., urology, 
obstetrics and gynecology, internal medicine, and ICU) in 
Shahrekord during April to October, 2016. The inpatients 
had acquired UTI 48-72 hours after admission and their 
first urinary culture was negative. The study protocol was 
approved by Shahrekord University of Medical Sciences 
under the code IR.SKUMS.REC.1394.282. First, the 
samples were cultured on blood agar and eosin methylene 
blue (HiMedia Company, India) and then identified by 
biochemical differential tests such as triple sugar iron agar, 
Simon citrate, methyl red/Voges-Proskauer, indole motility, 
oxidase and catalase. After the identification and phenotypic 
confirmation of E. coli, the colony of pure bacteria was 
stored for subsequent tests. For this purpose, the pure 
colony was inoculated in 1.5 microtubes containing 700 
μL of sterilized TSB culture medium and incubated at 37°C 
overnight. After the growth, 300 μL of sterilized glycerol 
was added to it and stored under -70°C in the freezer. To 
determine the antibiotic resistance, a suspension of pure 
bacteria equivalent to the 0.5 McFarland was prepared 
and then passaged on the surface of Mueller-Hinton agar 
medium and incubated at 37°C for 18-24 hours. Antibiotic 
susceptibility was determined by the disk diffusion (Kirby-
Bauer) method for two antibiotics, namely, meropenem 
(10 μg) and imipenem (10 μg) obtained from MAST 
Company, UK. After the incubation, the diameter of the 
growth inhibition zone was measured and interpreted in 
accordance with the CLSI Table. In addition, E. coli ATCC 
25922 was used for the quality control of susceptibility 
testing. MIC was determined by using the E-test strips 
(Liofilchem, Italy) at a concentration ranging from 0.002 
to 32 mg/L. Next, bacterial suspension was prepared from 
pure cultures to match the turbidity of the 0.5 McFarland 
and cultured on the Mueller-Hinton agar. Then, the strip 
was placed on the medium and incubated at 37°C for 
16-18 hours. The antibiotic release from the strip into 
the surrounding area formed an oval zone and the MIC 
extended to where it crossed the strip (14-18).
Results
The clinical samples of inpatients with UTI in different 
wards of Hajar and Kashani hospitals in Shahrekord were 
isolated, the details of which are presented in Table 1. As 
shown in Table 1, most isolates were obtained from the 
inpatients in the urology department. According to the 
results of the disk diffusion method, 21 and 20 isolates 
of E. coli were resistant to meropenem and imipenem, 
respectively, and 5 isolates had intermediate resistance 
(semi-sensitive). 
The highest number of resistant isolates of E. coli to 
meropenem and imipenem was isolated from the urology 
department, and none of the isolated strains from the 
internal medicine department had MIC ≥4 for meropenem.
The E-test strips were read from the top (high 
concentrations) to the bottom (low concentrations of the 
antibiotic) after 18 hours of incubation (Figure 1 and 2). 
According to the E-test results, 20 isolates were resistant 
to meropenem and 13 isolates to imipenem (MIC ≥4), 
indicating the high accuracy of the E-test method compared 
to the disk diffusion method for detecting resistant and 
semi-sensitive strains. The frequency of carbapenem-
resistant and sensitive isolates is presented in Table 2. 
Discussion
Opportunistic bacteria are the cause of nosocomial 
infections in different hospital wards and cause certain 
infections such as pneumonia, UTIs, and bacteremia after 
hospitalization. The underlying factors such as surgery, 
the weakness of the inpatient’s immune system, and long-
term hospital stay contribute to the acquisition of these 
infections. Further, E. coli, as the most common cause 
of UTIs, is considered as an important pathogen in the 
development of neonatal meningitis, respiratory infections, 
sepsis, fever and frequent urination, and disseminated 
intravascular coagulation in the inpatients in different 
wards of the hospital. Furthermore, antibiotic resistance is 
very common among the E. coli strains, which is due to the 
acquisition of multiple resistance factors. Today, bacterial 
resistance to various antibiotics has become a global problem 
and the uncontrolled administration of antibiotics for the 
treatment of bacterial infections has led to the selection 
Table 1. The frequency distribution of Escherichia coli isolated from clinical 
ward
Clinical Ward
E. coli
(No.)
Resistant to 
Meropenem (MIC≥4)
Resistant to 
Imipenem (MIC≥4)
Urology 33 10 7
Gynecology 
and obstetrics
16 4 2
Infection 14 5 1
Internal 12 0 2
Intensive care 
unit
5 1 1
Table 2. The frequencies of strains according to the minimum inhibitory 
concentrations of imipenem and meropenem
Antibiotics R(MIC≥4)
I
(4>MIC≥1)
S
(MIC<1)
Meropenem 20 8 52
Imipenem 13 6 61
Note. MIC: minimum inhibitory concentration. 
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of resistant strains (19). Antibiotic resistance patterns 
among nosocomial pathogenic bacteria may significantly 
vary from one country to another or in different regions 
of a country (20). Moreover, most pathogens are relatively 
resistant to some of the new antibiotics such as extended-
spectrum cephalosporins (e.g., cefotaxime and ceftazidime). 
Previously, imipenem was considered the most active drug 
for the infections. Recently, however, evidence demonstrates 
the spread of imipenem-resistant strains (21,22). The wide 
emergence of resistance to imipenem and meropenem is a 
serious threat to future treatment. Additionally, antibiotic 
resistance and susceptibility vary from country to country 
due to environmental factors and the use of different 
antimicrobial agents (23). Previous research has also 
confirmed the selection of the E-test method as a precise 
and sensitive method for determining the susceptibility of 
bacteria to antibiotics (24). In a similar study conducted 
by Nobari et al regarding the investigation of resistance to 
carbapenems on 180 isolates, it was revealed that 42, 29, 
and 14 isolates were resistant to meropenem, ertapenem, 
and imipenem, respectively (25). Therefore, resistance to 
E. coli appears to be constantly changing and it is essential 
to determine this change in different regions. In a study 
by Simhon et al, the sensitivity of imipenem decreased 
from 98% in 1990 to 64.1% in 2000 and the ciprofloxacin 
sensitivity reduced from 50.5% to 13% (26). Additionally, 
Bora et al. investigated resistance to carbapenems in E. coli 
and Klebsiella pneumoniae strains by using phenotypic tests 
and found that 41 of 216 E. coli isolates and 39 of 185 
K. pneumoniae isolates were resistant to carbapenems (27). 
Similarly, in their study in Al-Zahra hospital of Isfahan 
between the time period of March 2012 and December 
2012, Moayednia et al reported that 9, 14, and 8 out of 
720 E. coli isolates were resistant to meropenem, imipenem, 
and ertapenem, respectively, showing a lower resistance rate 
to meropenem and imipenem in the past compared to our 
current study (28). In a study conducted by Shahcheraghi 
et al in Tehran, 9 out of 244 isolates of E. coli were identified 
as meropenem-resistant, 1 isolate as imipenem-resistant, 
and 2 isolates as ertapenem-resistant (29). In addition, a 
study in a hospital in northern Palestine by Adwan et al on 
79 isolates of E. coli showed that 30 and 35 isolates were 
resistant to meropenem and imipenem, respectively, which 
can represent an increased resistance to another region of 
the world (30). This is also consistent with the results of 
a study by Kanchanadevi and Sekaran in which 25 out 
of 76 E. coli isolates, 2 out of 9 Klebsiella isolates, and 42 
out of 60 Pseudomonas isolates were resistant to imipenem 
according to the E-test (31). Resistance to carbapenems 
is very important because if the isolates from nosocomial 
infections are resistant to carbapenems, they will be also 
resistant to other antibiotics. Therefore, other antibiotics 
such as carbapenem-Sulbactam, colistin, or tigecycline 
should be used to treat these types of infections. Studying 
the resistance rate of E. coli isolates will provide adequate 
information for physicians to develop appropriate methods 
for the treatment of the infections due to this bacterium 
(2).
Conclusion
This study indicates a significant prevalence of resistance 
to the mentioned antibiotics, and this could be an alarm 
signal for the Healthcare. 
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